

Ref. No. JPL/CS/1411/2017

Date : 31st January, 2017.

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Reg.: **Regulation 30 (2) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Sub.: **Outcome of Board Meeting held today, i.e. 31st January, 2017 – Results for the Quarter ended 31st December, 2016.**

Dear Sir,

Kindly note that the Audit Committee have reviewed and the Board of Directors of the Company have approved the unaudited financial results for the quarter ended on 31st December, 2016 during their respective meetings held today, i.e. on 31st January, 2017.

The unaudited financial results of the Company for the quarter from 1st October, 2016 to 31st December, 2016 duly signed in the format specified under clause 30 (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, is enclosed.


Also enclosed along with is the limited audit review report of the Auditors of the Company, on the Unaudited Financial Results for the quarter ended on 31st December, 2016.

The Meeting of the Board of Directors of the Company commenced at 12.00 noon and concluded at 3.55 p.m.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Ltd.,



(ASHISH SHAH)
Company Secretary.


Encl.: As Stated Above.

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 

Statement of Standalone Unaudited Financial Results for the Quarter & Nine months Ended on 31/12/2016

PART-I		(Rs. in Lacs except per share data)				(Rs. In Lacs)	
Sr. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous year ended	Previous year ended
		31/12/2016	30/09/2016	31/12/2015	31/12/2016	31/12/2015	31/03/2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
(a)	Net Sales/Income from Operations (Net of excise	2485.05	2861.30	2406.10	7569.56	7102.98	9294.13
(b)	Other Operating Income	5.61	7.81	14.36	20.98	57.35	64.37
	Total income from Operations (net)	2490.66	2869.11	2420.46	7590.54	7160.33	9358.50
2	Expenses						
(a)	Cost of Materials Consumed	229.24	157.27	201.43	549.62	556.30	670.25
(b)	Purchase of Stock-in-trade	709.25	703.06	556.94	1792.96	1754.11	2218.59
(c)	Changes in inventories of Finished Goods, Work-in Progress and Stock-in-trade	-220.05	19.69	-55.18	-20.78	-163.51	-120.80
(d)	Employee benefit expenses	644.80	558.84	533.43	1820.25	1591.75	2149.02
(e)	Depreciation and Amortisation Expense	45.13	44.65	51.87	133.89	144.35	199.17
(f)	other expenses	690.63	736.59	694.70	2043.14	2046.53	2795.56
	Total Expenses	2099.01	2220.10	1983.19	6319.09	5929.53	7911.79
3	Profit from operations before other income, finance costs and exceptional items (1-2)	391.65	649.01	437.27	1271.45	1230.80	1446.71
4	other income	65.87	61.97	67.23	188.04	185.67	273.40
5	Profit from ordinary activities before finance costs and exceptional items (3 + 4)	457.52	710.98	504.50	1459.49	1416.47	1720.11
6	Finance Costs	8.55	11.15	8.01	28.37	25.74	37.81
7	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	448.97	699.83	496.49	1431.12	1390.73	1682.30
8	Exceptional Items	-0.52	0.75	-0.10	12.39	0.00	0.54
9	Profit from ordinary activities before tax (7 + 8)	448.46	700.58	496.39	1443.51	1390.73	1682.83
10	Tax Expense	153.35	197.58	146.14	450.45	442.20	604.93
11	Net Profit from ordinary activities after tax (9 - 10)	295.11	503.00	350.25	993.06	948.53	1077.90
12	Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit for the period (11 + 12)	295.11	503.00	350.25	993.06	948.53	1077.90
14	Paid-up equity share capital (F.V. Rs. 10/- each)	464.93	464.93	464.93	464.93	464.93	464.93
15	Reserve excluding Revaluation Reserves (as per balance sheet of previous accounting year)	0.00	0.00	0.00	0.00	0.00	3553.94
16	Earnings Per Share (before and after extraordinary items) Basic and Diluted	6.35	10.82	7.53	21.36	20.40	23.18

 By order of the Board
 For Jenburkt Pharmaceuticals Ltd.



 (Ashish U. Bhuta)
 Chairman and Managing Director.



 Place : Mumbai
 Date : 31st January, 2017






Dilip. L. Arora

B.Com (Hons.), F.C.A

D.L.ARORA & Co.
CHARTERED ACCOUNTANTS

**LIMITED REVIEW REPORT TO THE BOARD OF DIRECTORS OF JENBURKT
PHARMACEUTICALS LIMITED**

TO
THE BOARD OF DIRECTORS,
JENBURKT PHARMACEUTICALS LIMITED,
Mumbai

We have reviewed the accompanying statement of unaudited statement of financial result of **Jenburkt Pharmaceuticals Limited** ("the company"), for the quarter ended on December 31, 2016 (" the statement") , being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016 .This statement is the responsibility of the Company's Management and has been approved by the Board of Directors . Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 , "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly , we do not express an audit opinion .

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by circular no. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai.
Date: 31/01/2017

E:\My Documents - 1\Jenburk\Limited review report\JAN-2017.



For D.L.Arora & Co.
Chartered Accountants
FRN.: 100545W

Dilip Arora
Proprietor
M. No.: 036152